World Immunotherapy Congress - Agenda Day 1

 

World Immunotherapy Congress 2018, Day 1

08:00 Registration Opens

08:30 Conference doors open

08:45

Welcome from Terrapinn

Opening keynotes

08:55

Chair's opening remarks

Pascal Touchon
09:00

Novartis: CART Innovation Journey

  • From academic lab to FDA approval: a 5 yr journey
  • Tisagenleucleceul a transformative therapy in ALL and DLBCL
  • Key challenges for global access to patients
  • Future innovations in CART
Joseph Eid
09:20

Precision medicine in the era of immunotherapy

  • Why do we need new biomarkers?
  • Is tumor mutation burden the better single marker?
  • Do we need a multiparameter biomarker analyses or composite biomarker?
  • What are some potential new biomarkers?
Panel discussion
09:40

Senior-level panel: Immunotherapy strategies for oncology

  • Short 5 minute presentations outlining strategies developing immunotherapy for oncology, given by 6 high level representatives from differing company sizes
  • Panel discussion talking about how strategies for cancer immunotherapy differ between companies, and advantages and disadvantages for both
  • Top level speakers representing big pharma, large biotech and mid-sized biotech

10:20 Networking refreshment break

round tables
11:35

Plenary round table session

Table 1: Title TBC
Mark Lowdell

Mark Lowdell, Director of Cellular Therapy, Royal Free London NHS Foundation Trust

Table 3: Immunotherapy for solid tumours
Table 5: Scale-up and commercialisation of cell therapy products
Prentice Curry

Prentice Curry, Vice President Quality and Operations, Kite Pharma Inc

Table 6: Targeted vs no targeted treatment in arthritis diseases
Dr Ahuva Nissim

Dr Ahuva Nissim, Professor, William Harvey Research Institute

12:35 Networking Lunch

Immune-Checkpoint Inhibitors

Cell Therapy

Chaired by Shane Olwill, Head of Immuno-Oncology, Pieris Pharmaceuticals

Chaired by Matthew Hewitt, Director, Tumour Immunology & Microenvironment, Bellicum Pharmaceuticals

Immunotherapy - Immune Checkpoint Inhibitors
14:10

Selective SIRP-alpha antibodies: next-generation checkpoint inhibitors of myeloid cells

  • SIRPα is known as a myeloid cells checkpoint controlling macrophage phagocytosis of CD47-expressing targets.
  • SIRPα also controls antigen uptake, processing and cross-presentation in dendritic cells, as well as chemokine secretion and motility of macrophages, thereby indirectly modulating intensity and location of T cell responses.
  • Selective SIRPα antagonist antibodies have been shown to increase anti-tumor T cell responses in orthotopic cancer models, to increase intratumor cell migration and to synergize with anti-PD1/PDL1 antibodies.
  • Boehringer Ingelheim and OSE Immunotherapeutics entered into a global license and collaboration agreement in immuno-oncology to develop OSE-172/BI765063, a novel selective SIRPα antagonist antibody.
Immunotherapy - Cell Therapy
14:10

Gene-edited CAR T

  • Allogenic CAR T-cells have shown they can work in the clinic
  • We have pipeline covering various indications in the Hem oncology space
  • TALEN(r) mediated gene editing allows addressing CAR T-cell persistence and provides solutions for solid tumors
  • Acceleration of manufacturing production
Immunotherapy - Cell Therapy
14:30

PRS-343 (4-1BB / HER2) is a first-in-class T-Cell agonist which drives tumor localized activation of the immune system

  • Rationale for targeting 4-1BB and other costimulatory receptors
  • Preclinical characterisation of PRS-343 as a differentiated 4-1BB agonist
Immunotherapy - Cell Therapy
14:30

Three next generation immuno-oncology

  • 2 novel allogeneic Immuno-Oncology cell types
  • Allogenic NK and mesodermal cellular oncology platforms
  • siRNA platform targeting novel oncology targets and MDSC cells
  • Preliminary data and partnering opportunities
Immunotherapy - Immune Checkpoint Inhibitors
14:50

Targeting immune checkpoints with Humabody VH therapeutics

  • Outline approach to developing differentiated Immuno oncology therapeutics
  • BiParatopic PD-1 inhibitor which shows efficacy in an anti-PD-1 insensitive in vivo model
  • BiSpecific molecule inhibiting both PD-1 and LAG3 for overcoming resistance or insensitivity to PD-1 inhibition
  • Targeted IO approach in which T-cell co-stimulation is focused away from the periphery and into the tumour microenvironment in order to improve the narrow therapeutic index observed with standard T-cell agonist antibodies
Immunotherapy - Cell Therapy
14:50

NKG2D based CAR T cell therapy for cancer

  • T cells engineered to express a NKG2D based chimeric antigen receptor (CYAD-01) are endowed with the potential to target a wide range of haematological and solid tumors
  • The observation of a complete response in a relapsed / refractory AML patient receiving CYAD-01 cells in the absence of pre-conditioning chemotherapy provides clinical support for the approach.
  • Our developments in the allogeneic space focus on exploring non-gene edited approaches to deal with the graft versus host response and this forms the basis of our first clinical testing of the NKG2D CAR in the allogeneic setting.
Immunotherapy - Immune Checkpoint Inhibitors
15:10

IgA antibodies for the recruitment of myeloid effector cells in tumour immunotherapy

  • Myeloid cells constitute a significant population of the tumour immune cell infiltrate
  • Antibodies of IgA isotype effectively activate tumour cell killing by myeloid cells
  • Tumour cell killing by myeloid cells is enhanced by blockade of CD47/SIRPa interactions
Immunotherapy - Cell Therapy
15:10

Assessing strategies to neutralize the pro-tumour microenvironment to increase GoCAR-T efficacy in solid tumours

  • The utility of using in-vitro spheroid assays to mimic the in vivo tumour microenvironment to assess strategies in overcoming the pro-tumour microenvironment
  • Assessing the translatability of in vitro models to in vivo rodent models of oncology to guide lead candidate advancement
  • Whether Bellicum’s molecular activation/kill switches engineered into CAR T-cells are resistant to immunosuppressive pathways and increase solid tumour efficacy

15:30 Networking Break

Immune checkpoint inhibitors

Chaired by Dario Neri, Founder, Philogen; Professor of Chemistry and Applied Biology, Swiss Federal Institute of Technology Zurich

Immunotherapy - Immune Checkpoint Inhibitors
16:30

Antibody-cytokine fusions for cancer therapy

  • Antibody-cytokine fusions based on IL2, TNF or IL12: preclinical results
  • Results of on-going clinical trials
  • Rationale for combinations
Immunotherapy - Cell Therapy
16:30

Application of T4 CAR T-cell Immunotherapy in solid tumours: pre-clinical development and phase I trial results against head and neck cancer

  • We have generated a CAR (T28z) that utilises the promiscuous ErbB receptor binding peptide, T1E, to target 8/9 of the dimeric combinations formed by this family of growth factor receptors. This is co-expressed with a novel cytokine receptor, which enables selective growth of transduced T-cells in response to the poor T-cell mitogen, IL-4. Together, this construct is referred to as ‘T4 Immunotherapy'
  • The talk will comprise details of the pre-clinical efficacy and safety testing of T4 Immunotherapy in various tumour models, including head and neck cancer, ovarian cancer and mesothelioma.
  • I will outline the scope and design of an ongoing Phase I clinical trial for patients with locally recurrent and refractory squamous cell carcinoma of the head and neck.
  • An update of safety and efficacy data for the 15 patients so far treated will also be presented.
David Marc Davies, Post-doctoral Research Scientist, King's College London
Immunotherapy - Immune Checkpoint Inhibitors
16:50

Next generation cancer immunotherapy using IL-2/antibody complexes

  • Present our re-direct strategy to increase the efficacy of IL-2 therapy and decrease toxicity
  • Antibody development and in vitro data
  • In vivo data in mice (and possibly monkeys)
  • Late pre-clinical development activities
Immunotherapy - Cell Therapy
16:50

Cell encapsulation technology for personalized Immunotherapy:MVX-ONCO-1 in Phase 2 efficacy study

  • Personalized immunotherapy
  • Optimal adjuvant delivery
  • Cell encapsulation Technology
  • Clinical Trial
Nicolas Mach, Chief Scientific Officer, MaxiVax
Immunotherapy - Immune Checkpoint Inhibitors
17:10

ImmTAC(TM) technology platform: novel strategies to increase immunotherapy efficacy

  • Generating high-affinity, bi-specific TCR-molecules for cancer therapy
  • Addressing intra-tumour heterogeneity
  • Strategies to enhance tumour immunogenicity
Immunotherapy - Immune Checkpoint Inhibitors
17:30

Bi- and trifunctional antibody-fusion proteins for cancer therapy

  • Combination of IL-15 with costimulatory TNF-superfamily ligands
  • Mode of action
  • Format development
Immunotherapy - Immune Checkpoint Inhibitors
17:50

The role of Fc receptor-IgG interactions in the therapeutic activity of checkpoint antibodies

  • FcR pathways involved in the therapeutic mechanism of different checkpoint mAbs
  • Harnessing Fc Receptors for optimizing the anti-tumour activity of checkpoint mAbs
  • Mouse models to study efficacy and toxicity of human checkpoint mAbs and for screening Fc-engineered clinical candidates.
  • Strategies to widen the therapeutic window of immunomodulatory mAbs

18:10 Offsite networking drinks

last published: 15/Oct/18 13:05 GMT

 

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates